NeuExcell Therapeutics: Funding, Investors & Team (Sep 2026)
NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. We have developed a disruptive neural repair technology that utilizes in vivo astrocyte-to-neuron conversion. Our vision is to improve the quality of life of millions of patients worldwide who are suffering from neurodegenerative conditions by using the power of gene therapy to restore damaged neural tissue.
NeuExcell Therapeutics has raised $15.0M across 1 funding round on record, the most recent a Seed of $15.0M announced in May 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NeuExcell Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2023.
NeuExcell Therapeutics Funding Rounds
NeuExcell Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
NeuExcell Therapeutics Funding Compared to Other Biotechnology Startups
NeuExcell Therapeutics' latest round of $15.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NeuExcell Therapeutics in Biotechnology and State College
Companies Similar to NeuExcell Therapeutics
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
NeuExcell Therapeutics Funding FAQs
What does NeuExcell Therapeutics do?
NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. We have developed a disruptive neural repair technology that utilizes in vivo astrocyte-to-neuron conversion. Our vision is to improve the quality of life of millions of patients worldwide who are suffering from neurodegenerative conditions by using the power of gene therapy to restore damaged neural tissue.
How much funding has NeuExcell Therapeutics raised?
NeuExcell Therapeutics has raised $15.0M across 1 round on record. The most recent is a Seed of $15.0M announced in May 2023.
When did NeuExcell Therapeutics last raise funding?
NeuExcell Therapeutics' most recent funding round on record is a Seed of $15.0M, announced in May 2023.
Who founded NeuExcell Therapeutics?
FundedIQ lists Jie Xu (Founder) at NeuExcell Therapeutics.
Where is NeuExcell Therapeutics headquartered?
NeuExcell Therapeutics is based in State College, Pennsylvania, United States.
How many employees does NeuExcell Therapeutics have?
NeuExcell Therapeutics is in the 11-50 employee band.
How does NeuExcell Therapeutics' funding compare to other Biotechnology startups?
NeuExcell Therapeutics' latest round of $15.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's NeuExcell Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NeuExcell Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.